Price$1.84+0.12 (+6.98%)
01:30 PM07:45 PM
News · 26 weeks39+75%
2025-12-072026-05-31
Mix2190d
- SEC Filings9(43%)
- Other5(24%)
- Insider5(24%)
- Earnings1(5%)
- Leadership1(5%)
Latest news
25 items- PRiBio to Participate in Upcoming Healthcare Investor ConferencesSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference. Jefferies Global Healthcare ConferencePresentation Date: Thursday, June 4, 2026Time: 11:40 a.m. ETLocation: Marriott Marquis, New York A livestream of the event can be accessed link, and a replay of the presenta
- PRiBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with ObesityIBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the Company's most advanced obesity and cardiometabolic asset and its first program to enter human clinical dev
- INSIDERSEC Form 4 filed by Director Stoner Elizabeth4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stoner Elizabeth3 - iBio, Inc. (0001420720) (Issuer)
- SECSEC Form 10-Q filed by iBio Inc.10-Q - iBio, Inc. (0001420720) (Filer)
- SECiBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate UpdateReceived regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporat
- SECiBio Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of DirectorsSAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors. Dr. Stoner is appointed as an independent member of the Board of Directors and as a member of the Compensation Committee, following the transition of Eef Schimmelpennink from this position, who has stepped down from the Board. "We are excited to welcome Liz to our Board of Directors at a pivotal moment in iBio's evolution as clinical-staged company," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Of
- SECSEC Form 424B3 filed by iBio Inc.424B3 - iBio, Inc. (0001420720) (Filer)
- SECAmendment: iBio Inc. filed SEC Form 8-K: Other Events8-K/A - iBio, Inc. (0001420720) (Filer)
- SECiBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in AustraliaIBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or "the Company"), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced IBIO-600 has received Clinical Trial Notification (CTN) acknowledgement from Australia's Therapeutic Goods Administration (TGA) and ethics approval from a Human Research Ethics Committee (HREC), enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia. The
- INSIDERSEC Form 4 filed by Banjak Marc4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by Duran Felipe4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by Brenner Martin4 - iBio, Inc. (0001420720) (Issuer)
- PRiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo
- SECiBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight LossSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. The preclinical body composition data demonstrates IBIO-610 reduced fat mass in obese NHPs compared to vehicle-treated obese NHPs, in a small, not statistically powered study. Following two once-every-eight-week dosing, IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2%, with only a slight up-tick in lean mass following treatment. This fat-sele
- SECSEC Form EFFECT filed by iBio Inc.EFFECT - iBio, Inc. (0001420720) (Filer)
- SECSEC Form 424B5 filed by iBio Inc.424B5 - iBio, Inc. (0001420720) (Filer)
- SECiBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- SECSEC Form S-3 filed by iBio Inc.S-3 - iBio, Inc. (0001420720) (Filer)
- PRiBio to Participate in Upcoming Investor ConferencesSAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, February 26, 2026Time: 2:00 p.m. ETLocation: VirtualA livestream of the event can be accessed here. Leerink Global Healthcare ConferencePresentation Date: Monday, March 9, 2026 Time: 4:20
- SECSEC Form 10-Q filed by iBio Inc.10-Q - iBio, Inc. (0001420720) (Filer)
IBIO FAQ
6 questionsWhat does iBio Inc. do?
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical...Where does IBIO stock trade?
iBio Inc. (IBIO) is listed on AMEX.What sector and industry is IBIO in?
iBio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IBIO?
iBio Inc. has had 5 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $500.00 price target on 2025-10-21. Recent price targets range from $150.00 to $500.00.What companies are similar to IBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IBIO side-by-side with any of them on Quantisnow.How can I track IBIO on Quantisnow?
Quantisnow aggregates iBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBIO to receive live email and push alerts on every new disclosure.